KR20240121186A - 주사용 조성물, 이를 포함하는 약학적 제제 및 이의 제조 방법 - Google Patents
주사용 조성물, 이를 포함하는 약학적 제제 및 이의 제조 방법 Download PDFInfo
- Publication number
- KR20240121186A KR20240121186A KR1020240014951A KR20240014951A KR20240121186A KR 20240121186 A KR20240121186 A KR 20240121186A KR 1020240014951 A KR1020240014951 A KR 1020240014951A KR 20240014951 A KR20240014951 A KR 20240014951A KR 20240121186 A KR20240121186 A KR 20240121186A
- Authority
- KR
- South Korea
- Prior art keywords
- injectable composition
- albumin
- sbe
- citrate salt
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020230013947 | 2023-02-01 | ||
| KR20230013947 | 2023-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240121186A true KR20240121186A (ko) | 2024-08-08 |
Family
ID=92024104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020240014951A Pending KR20240121186A (ko) | 2023-02-01 | 2024-01-31 | 주사용 조성물, 이를 포함하는 약학적 제제 및 이의 제조 방법 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4658244A1 (https=) |
| JP (1) | JP2026505092A (https=) |
| KR (1) | KR20240121186A (https=) |
| CN (1) | CN118415999A (https=) |
| AR (1) | AR131668A1 (https=) |
| AU (1) | AU2024215883A1 (https=) |
| CL (1) | CL2025002270A1 (https=) |
| CO (1) | CO2025011347A2 (https=) |
| DO (1) | DOP2025000185A (https=) |
| IL (1) | IL322431A (https=) |
| JO (1) | JOP20250189A1 (https=) |
| MX (1) | MX2025008735A (https=) |
| PE (1) | PE20252396A1 (https=) |
| TW (1) | TW202432120A (https=) |
| WO (1) | WO2024161316A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120827558A (zh) * | 2024-04-19 | 2025-10-24 | 丽珠医药集团股份有限公司 | 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101777971B1 (ko) | 2016-07-05 | 2017-09-12 | 제일약품주식회사 | 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1682133A1 (en) * | 2003-11-03 | 2006-07-26 | AstraZeneca AB | Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux |
| AR051041A1 (es) * | 2004-10-04 | 2006-12-13 | Altana Pharma Ag | Bencimidazoles triciclicos condensados |
| FI20086158A0 (fi) * | 2008-12-03 | 2008-12-03 | Mikael Dahlstroem | Imidatsopyridiinijohdannaiset |
| GB0906470D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
-
2023
- 2023-11-20 TW TW112144715A patent/TW202432120A/zh unknown
- 2023-11-29 CN CN202311609051.XA patent/CN118415999A/zh active Pending
-
2024
- 2024-01-23 AR ARP240100149A patent/AR131668A1/es unknown
- 2024-01-31 PE PE2025001666A patent/PE20252396A1/es unknown
- 2024-01-31 AU AU2024215883A patent/AU2024215883A1/en active Pending
- 2024-01-31 KR KR1020240014951A patent/KR20240121186A/ko active Pending
- 2024-01-31 IL IL322431A patent/IL322431A/en unknown
- 2024-01-31 EP EP24749813.2A patent/EP4658244A1/en active Pending
- 2024-01-31 WO PCT/IB2024/050869 patent/WO2024161316A1/en not_active Ceased
- 2024-01-31 JP JP2025544851A patent/JP2026505092A/ja active Pending
-
2025
- 2025-07-25 MX MX2025008735A patent/MX2025008735A/es unknown
- 2025-07-28 JO JOJO/P/2025/0189A patent/JOP20250189A1/ar unknown
- 2025-07-30 CL CL2025002270A patent/CL2025002270A1/es unknown
- 2025-07-31 DO DO2025000185A patent/DOP2025000185A/es unknown
- 2025-08-22 CO CONC2025/0011347A patent/CO2025011347A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101777971B1 (ko) | 2016-07-05 | 2017-09-12 | 제일약품주식회사 | 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| AR131668A1 (es) | 2025-04-16 |
| CO2025011347A2 (es) | 2025-09-18 |
| IL322431A (en) | 2025-09-01 |
| AU2024215883A1 (en) | 2025-07-31 |
| JP2026505092A (ja) | 2026-02-10 |
| CN118415999A (zh) | 2024-08-02 |
| MX2025008735A (es) | 2025-11-03 |
| DOP2025000185A (es) | 2026-02-15 |
| EP4658244A1 (en) | 2025-12-10 |
| CL2025002270A1 (es) | 2025-10-03 |
| TW202432120A (zh) | 2024-08-16 |
| JOP20250189A1 (ar) | 2025-07-28 |
| PE20252396A1 (es) | 2025-10-10 |
| WO2024161316A1 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
| US7678776B2 (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| EP0519428A2 (en) | Cyclodextrin composition | |
| EP0649655A1 (en) | Injectable solutions containing anti-ulcer benzimidazoles and amides | |
| CA2111560A1 (en) | Stable pharmaceutical composition of fumagillol derivatives | |
| EP0555693A1 (en) | Method of producing highly watersoluble cyclodextrin complex | |
| CN110876259B (zh) | 注射用组合物 | |
| JP6461945B2 (ja) | ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法 | |
| HU226778B1 (en) | Injection and injection kit containing omeprazole and its analogs | |
| JPH0413325B2 (https=) | ||
| KR101829685B1 (ko) | 안정성 및 용해도가 개선된 주사용 조성물 | |
| CN111093625A (zh) | 达托霉素制剂 | |
| KR101731155B1 (ko) | 안정화된 보리코나졸 조성물 | |
| PL199868B1 (pl) | Trwały ciekły preparat inhibitora H⁺ , K⁺-ATPazy, sposób jego wytwarzania, zastosowanie glikolu polietylenowego i soli sodowej lub potasowej inhibitora H⁺ , K⁺-ATPazy oraz zastosowanie tego preparatu | |
| KR20240121186A (ko) | 주사용 조성물, 이를 포함하는 약학적 제제 및 이의 제조 방법 | |
| JP6063064B2 (ja) | 安定したノカチアシン凍結乾燥製剤 | |
| CA1160571A (en) | Antitumor compositions | |
| HU199289B (en) | Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid | |
| JP2022500350A (ja) | 安定したアザシチジン含有医薬組成物の製造方法 | |
| HK40111340A (zh) | 可注射组合物、包含其的药物制剂以及制备该组合物的方法 | |
| PL203300B1 (pl) | Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego | |
| JPH0343251B2 (https=) | ||
| JP2019504042A (ja) | 経口製剤およびその製造方法 | |
| US4425348A (en) | Antitumor compositions | |
| US4322424A (en) | Crystalline glucoconate salt of m-AMSA and compositions containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
St.27 status event code: A-0-1-A10-A12-nap-PA0109 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |